The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | The value of MRD assessment in lymphoma
Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, describes the significance of monitoring minimal residual disease (MRD) in lymphoma. MRD detection can enable accurate evaluation of treatment response and help guide patients to the right treatment path. In the case of the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant mantle cell lymphoma (MCL), patients who were MRD positive continued treatment. Dr Kumar additionally highlights the need for more research to evaluate the role of MRD in diffuse large B-cell lymphoma (DLBCL) surveillance. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
